|
A recent study reported by the study author—Dr. H. Ralph Schumacher, Jr., a professor of medicine at the University of Pennsylvania School of Medicine in the United States, proved that a protein-inhibitor drug rilonacept (Arcalyst) appeared to significantly reduce the occurrence of gout flare-ups. The researchers also published their study results in the journal Arthritis & Rheumatism.
Gout patients usually suffer from a sudden outburst or worsening of gout that can last days or weeks. The researchers gathered 83 gout patients who had a history of gout flare-ups and a high level of uric acid from 27 U.S. study centers. They divided those patients in half and gave one group injections of rilonacept for 16 weeks. The researchers found that only 15 percent of rilonacept group experienced flare-ups three months into the study, whereas the flare-ups rate was 45 percent in non-rilonacept patients. The study author, Dr. Schumacher, suggested that “Rilonacept appears safe and well tolerated and could increase patient adherence to long-term urate-lowering therapy.”
In addition to medical treatment, many doctors recommend that gout can be prevented by keeping healthy lifestyles, such as having a healthy diet, losing weight, and limiting alcohol consumption. Drinking plenty of nonalcoholic beverages, especially water, will help to remove uric acid from our bodies. Furthermore, avoiding or limiting consumption of high-purine foods like anchovies, sardines, scallops, asparagus, mushrooms, livers, and beef kidneys that can increase uric acid levels as well as doing exercises regularly may also help reducing the risk of developing gout.
|
|